Release date: 3/15/2022
Triple negative breast cancer (TNBC) accounts for 15% to 20% of all breast cancers and individuals diagnosed typically have worse outcomes than others diagnosed with other types of breast cancer. Recent research has identified novel agents with the hopes to improve patient outcomes. TNBC is more common among African American woman compared to white woman and the mortality rate is higher for African American woman than white woman. There are several reasons for this unfortunate outcome which includes clinicians not providing adequate care. This module will increase clinician awareness surrounding racial disparities in TNBC.
This activity is designed to meet the needs of Oncology professionals, physicians, physician assistants, nurses, nurse navigators, nurse practitioners, and pharmacists.
Upon completion of the educational activity, participants should be able to:
- Summarize opportunities to improve treatment of triple-negative breast cancer.
Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. If you have questions about this CE activity, please contact AKH Inc. at [email protected]
Credit provided by AKH, Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Center of Excellence Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Credit being awarded: .25 ANCC contact hours
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for .25 contact hours.
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and Lynx. AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. This activity is approved for .25 contact hour(s).
This activity is supported by an educational grant from Gilead Sciences Inc
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity.
None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed for these individuals have been mitigated.
Deborah C. Clark, PhD Senior Director of Professional Development
Dorothy Caputo, MA, BSN, RN Senior Director of Continuing Education & Compliance
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.